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Abstract. The aim of the present study was to determine 
whether chronic diseases (CD), such as hypertension, diabetes 
mellitus, dyslipidemia, heart diseases and cerebrovascular 
diseases, are occurrence risk factors and affect the survival 
of patients with gynecological cancers (GC). The correlations 
between CD and the characteristics and survival of 1,590 GC 
patients [685 with cervical cancer (CC), 613 with endometrial 
cancer (EM) and 292 with ovarian cancer (OV)] were inves-
tigated in the present study. Of the CD patients, 189 had CC 
(27.6%), 265 had EM (43.2%) and 72 had OV (24.7%). The inci-
dence of CD increased with age in GC patients. The number 
of CD patients aged ≥70 years, was 8.6‑fold higher in the CC 
group, 3.0-fold higher in the EM group, and 9.6-fold higher 
in the OV group compared with those aged <50 years. CD 
and excess body weight were associated with GC regardless 
of patient age. However, there was no correlation between CD 
and survival at any age in GC patients. These findings indicate 
that CD contribute to >24% of the occurrence risk factors in 
GC patients in Japan.
Introduction
The incidence of gynecological cancers (GC) has increased in 
Japan, with an estimated 30,964 newly diagnosed patients in 
2009. In recent years, the incidence of GC has increased among 
younger patients, as well as among older patients (1). The risk 
factors for GC differ by organ. For example, the development 
of invasive cervical cancer (CC) requires persistent infection 
by human papillomavirus (2,3). Several occurrence risk factors 
for endometrial cancer (EM) have been established, including 
excess body weight (4) and diabetes mellitus (DM) (5). The 
occurrence risk factors for ovarian cancer (OV) include age 
at diagnosis, family history of OV, infertility treatment and 
assisted fertilization, obesity and metabolic syndromes (6). 
Recently, metabolic conditions, such as obesity, hyperlipidemia 
and DM, have been attracting increasing attention with respect 
to OV incidence (7,8). Therefore, the onset of EM and OV 
appears to be associated with lifestyle and behavioral factors, 
such as dietary habits, physical activity, smoking and alcohol 
consumption.
Chronic diseases (CD) and cancer share common risk 
factors, including aging and unhealthy habits, such as 
smoking, poor diet, sedentary lifestyle, obesity and alcohol 
intake. CD include hypertension (HT), DM, dyslipidemia 
(DL), heart disease (HD) and cerebrovascular disease (CVD), 
and constitute >20% of the occurrence risk factors for various 
cancers (9). In 2017, the Japanese Ministry of Health, Labour 
and Welfare reported that 108,000 CD patients were aged 
<35 years, 3,141,000 CD patients were aged 35-64 years, and 
11,458,000 CD patients were aged ≥65 years among women 
without cancer in Japan (10).
The development rates of CD are rapidly increased by 
excess body weight (11), but there are no published details 
of the effect of CD on GC. Therefore, the aim of the present 
study was to investigate the correlations between CD and GC, 
including CC.
Patients and methods
Study population. The present retrospective study reviewed 
the medical records of 1,590 GC patients who were treated 
at the Department of Obstetrics and Gynecology of Okayama 
University Hospital (Okayama, Japan) between April 2004 
and December 2017. The study protocol was approved by the 
Institutional Review Board of Okayama University Hospital 
(1904-05). Several studies reported that the threshold for 
lowest risk of all-cause mortality was ~100 g alcohol/week and 
<10 cigarettes/day (12,13). All patients underwent a review of 
their medical history and lifestyle habits (smoking-positive: 
Current smokers of ≥10 cigarettes/day; alcohol intake‑positive: 
Alcohol intake of ≥14 g/day), physical examination and 
routine clinical staging. The patients were treated according 
to the Japan Society of Gynecologic Oncology clinical 
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guidelines (14-16). The treatment options for gynecological 
cancer included surgery, radiotherapy and/or chemotherapy, 
depending on tumor stage and additional risk factors.
Data collection. The patients were asked to complete 
questionnaires on their history of cardiac disease, lifestyle 
habits (smoking and alcohol intake), and medications for HT, 
DM and DL. The measurements included standard medical 
examinations, such as height, weight, blood pressure, fasting 
blood glucose, hemoglobin A1c and serum lipid profile, 
including triglyceride (TG), serum high-density lipoprotein 
cholesterol (HDL-C) and low-density lipoprotein cholesterol 
(LDL‑C) levels. Patients with HT were defined as those with 
blood pressure ≥140/90 mmHg, or those on antihypertensive 
medication. Patients with DM were defined as those with 
hemoglobin A1c ≥6.5%, or those receiving antidiabetic 
medication. Patients with DL were determined as those with 
TG ≥150 mg/dl, HDL‑C <40 mg/dl, and LDL‑C ≥140 mg/dl, 
or those receiving medication for DL. The presence of HD 
and CVD were assessed based on self-reports. Height and 
weight were measured on admission, prior to any therapeutic 
intervention. Body mass index (BMI) was defined according to 
the 2015 World Health Organization classification as follows: 
Underweight, <18.5 kg/m2; normal weight, 18.5‑24.99 kg/m2; 
overweight, 25.0-29.99 kg/m2; and obese, ≥30.0 kg/m2.
Statistical analysis. Data were analyzed using χ2 and 
Mann-Whitney U-tests for comparisons, and by one-way 
analysis of variance followed by Fisher's protected least 
significant difference test for all pairwise comparisons. 
Survival curves were constructed using the Kaplan-Meier 
method, and differences between survival curves were 
examined using the log-rank test. Analyses were performed 
using SPSS software, version 23.0 (IBM Corp.), with the 
significance level set at 0.05.
Results
Patient characteristics. CC, EM and OV patients were aged 
25-92, 23-91 and 15-84 years, respectively (median CC age, 
55.0 years; median EM age, 59.0 years; and median OC age, 
57.0 years). Age was divided into four groups: <50, 50-59, 
Table I. Incidence of GC among patients with chronic diseases in different age groups.
 CC EM OV
 ----------------------------------------------- ----------------------------------------------- -------------------------------------------------
Chronic diseases Number (%) Number (%) Number (%)
HT, age (years)
  <50  9 3.2 12 10 1 1.3
  50-59  16 11.6 34 17 13 14.9
  60-69  43 32.3 61 48.8 19 23.2
  ≥70  57 41.6 67 39.9 13 28.9
DM, age (years)
  <50  4 1.4 13 10.8 2 2.6
  50-59  10 7.2 17 8.5 3 3.4
  60-69  15 11.2 20 16 4 4.9
  ≥70  12 8.8 31 18.5 6 13.3
DL, age (years)
  <50  2 0.7 5 4.2 0 0
  50-59  4 2.9 18 9 8 9.2
  60-69  14 10.5 27 21.6 8 9.8
  ≥70  14 10.2 42 25 7 15.6
HD, age (years)
  <50  2 0.7 4 3.3 1 1.3
  50-59  2 1.4 6 3 2 2.3
  60-69  4 3 13 10.4 1 1.2
  ≥70  15 10.9 8 4.8 2 4.4
CVD, age (years)
  <50  3 1.1 0 0 0 0
  50-59  2 1.4 5 2.5 0 0
  60-69  6 4.5 6 4.8 3 3.7
  ≥70  13 9.5 6 3.6 3 6.7
GC, gynecological cancers; CC, cervical cancer; EM, endometrial cancer; OV, ovarian cancer; HT, hypertension; DM, diabetes mellitus; DL, 
dyslipidemia; HD, heart diseases; CVD, cerebrovascular diseases.
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60‑69 and ≥70 years. The <50 years group included 277 CC 
(40.4%), 120 EM (19.6%) and 78 OV (26.7%) patients; the 
50-59 years group included 138 CC (20.2%), 200 EM (32.6%) 
and 87 OV (29.8%) patients; the 60‑69 years group included 
133 CC (19.4%), 168 EM (27.4%) and 82 OV (28.1%) patients; 
and the ≥70 years group included 137 CC (20.0%), 125 EM 
(20.4%) and 45 OV (15.4%) patients.
The HT, DM, DL, HD and CVD patients in the <50 years 
group included 9, 4, 2, 2 and 3 CC patients, respectively 
(3.2, 1.4, 0.7, 0.7 and 1.1%, respectively); 12, 13, 5, 4 and 0 
EM patients, respectively (10.0, 10.8, 4.2, 3.3 and 0%, respec-
tively); and 1, 2, 0, 1 and 0 OV patients, respectively (1.3, 2.6, 
0, 1.3 and 0%, respectively). The HT, DM, DL, HD and CVD 
patients in the 50-59 years group included 16, 10, 4, 2 and 2 
CC patients, respectively (11.6, 7.2, 2.9, 1.4 and 1.4%, respec-
tively); 34, 17, 18, 6 and 5 EM patients, respectively (17.0, 
8.5, 9.0, 3.0 and 2.5%, respectively); and 13, 3, 8, 2 and 0 OV 
patients, respectively (14.9, 3.4, 9.2, 2.3 and 0%, respectively). 
Figure 1. The percentage of chronic diseases (CD) in cervical cancer (CC), 
endometrial cancer (EM) and ovarian cancer (OV) patients was examined in 
the four age groups: <50, 50‑59, 60‑69 and ≥70 years.
Table II. Baseline characteristics and CD in patients with gynecological cancers.
 CC EM OV
Baseline ------------------------------------------------------------- ------------------------------------------------------------ --------------------------------------------------------------
characteristics Number (%)  P-value Number (%) P-value Number (%) P-value
Stage   -   <0.001a   <0.001a
  I, II 437 63.8  460 75.0  139 47.6
  III, IV 248 36.2  153 25.0  153 52.4
HT   -   <0.001a   0.375
  Present 125 18.2  174 28.4  46 15.8
  Absent 560 81.8  439 71.6  246 84.2
DM   -   <0.001a    0.601
  Present 41 6  81 13.2  15 5.1
  Absent 644 94  532 86.8  277 94.9
DL   -   <0.001a   0.075
  Present 34 5  92 15.0  23 7.9
  Absent 651 95  521 85.0  269 92.1
HD   -   0.126   0.272
  Present 23 3.4  31 5.1  6 2.1
  Absent 662 96.6  582 94.9  286 97.9
CVD   -   0.453   0.229
  Present 24 3.5  17 2.8  6 2.1
  Absent 661 96.5  596 97.2  286 97.9
BMI, kg/m2   -   <0.001a   0.537
  <25.0 549 80.1  370 60.4  239 81.8
  ≥25.0 136 19.9  243 39.6  53 18.2
Smoking   -   <0.001a   <0.001a
  Negative 524 76.5  577 94.1  274 93.8
  Positive 161 23.5  36 5.9  18 6.2
Alcohol   -   <0.001a   0.026a
  Negative 609 88.9  580 94.6  273 93.5
  Positive 76 11.1  33 5.4  19 6.5
aStatistically significant difference. CD, chronic diseases; CC, cervical cancer; EM, endometrial cancer; OV, ovarian cancer; BMI, body mass 
index, HT, hypertension; DM, diabetes mellitus; DL, dyslipidemia; HD, heart diseases; CVD, cerebrovascular diseases.
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The HT, DM, DL, HD and CVD patients in the 60-69 years 
group included 43, 15, 14, 4 and 6 CC patients, respectively 
(32.3, 11.2, 10.5, 3.0 and 4.5%, respectively); 61, 20, 27, 13 and 
6 EM patients, respectively (48.8, 16.0, 21.6, 10.4 and 4.8%, 
respectively); and 19, 4, 8, 1 and 3 OV patients, respectively 
(23.2, 4.9, 9.8, 1.2 and 3.7%, respectively). Finally, the HT, DM, 
DL, HD and CVD patients in the ≥70 years group included 
57, 12, 14, 15 and 13 CC patients, respectively (41.6, 8.8, 10.2, 
10.9 and 9.5%, respectively); 67, 31, 42, 8 and 6 EM patients, 
respectively (39.9, 18.5, 25.0, 4.8 and 3.6%, respectively); and 
13, 6, 7, 2 and 3 OV patients, respectively (28.9, 13.3, 15.6, 4.4 
and 6.7%, respectively) (Table I).
The associations of each GC type [CC (n=685), EM 
(n=613) and OV (n=292)] with clinical characteristics (cancer 
stage, HT, DM, DL, HD, CVD, BMI, smoking and alcohol 
intake) were assessed (Table II). Regarding FIGO stage, 
there were significantly more EM patients with early‑stage 
disease compared with CC patients (P<0.001). Conversely, 
the number of advanced‑stage OV patients was significantly 
higher compared with CC patients (P<0.001). The incidence 
of HT, DM, DL and high BMI were significantly higher in EM 
patients compared with CC patients (all P<0.001). Furthermore, 
significantly more CC patients were smoking‑ and alcohol 
intake-positive compared with EM and OV patients (P<0.001, 
P<0.001, P<0.001 and P=0.026, respectively).
The effect of CD was examined by determining how many 
of CC, EM and OV patients in each of the four age groups had 
CD. CD patients were divided into 189 CC (27.6%), 265 EM 
(43.2%) and 72 OV (24.7%) patients. Patients in the <50 years 
group with CD included 19 CC (6.9%), 27 EM (22.5%) and 
4 OV (5.1%) patients. CD patients in the 50-59 years group 
included 29 CC (21.0%), 57 EM (28.5%) and 21 OV (24.1%) 
patients. CD patients in the 60-69 years group included 60 CC 
(45.1%), 98 EM (58.3%), and 25 OV (30.5%) patients. Finally, 
CD patients in the ≥70 years group included 81 CC (59.1%), 
83 EM (66.4%) and 22 OV (48.9%) patients. CC patients 
aged ≥70 years and EM patients aged 60‑69 and ≥70 years 
accounted for >50% of those with CD. Therefore, the number 
of patients with CD aged ≥70 years was 8.6‑fold higher in 
the CC group, 3.0-fold higher in the EM group, and 9.6-fold 
higher in the OV group compared with patients aged <50 years 
(Fig. 1).
CD was examined for its association with BMI, smoking 
and alcohol intake at any age in CC, EM and OV patients. 
BMI and CD were significantly associated in CC patients aged 
<50 and 50-59 years (P=0.025 and P=0.010, respectively). 
BMI and CD were significantly associated in all age groups 
in EM patients (P<0.001, P<0.001, P<0.001 and P=0.014, 
respectively). BMI and CD were significantly associated in 
OV patients aged 50‑59 and ≥70 years (P=0.043 and P=0.004, 
respectively; Fig. 2). However, there was no association 
between CD and smoking or alcohol intake at any age in CC, 
EM or OV patients.
In the present study, the median overall survival (OS) 
rates for patients with CC, EM and OV were 44.0, 40.0 and 
32.5 months, respectively. The follow-up period was 1-174, 
Figure 2. The association of body mass index (BMI) with chronic diseases (CD) and age (four groups: <50, 50‑59, 60‑69 and ≥70 years) was examined in 
cervical cancer (CC), endometrial cancer (EM) and ovarian cancer (OV) patients. *P<0.05; **P<0.005.
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1-146 and 1-132 months, respectively. The OS curves for the 
1,590 GC patients according to their CD are shown in Fig. 3. 
There was no significant correlation between CD and survival 
at any age in CC, EM or OV patients.
Discussion
The occurrence risk factors for cancer include smoking, 
an unhealthy diet, obesity, sedentary lifestyle, DM, HT and 
alcohol abuse, either alone or in combination. Accumulating 
evidence has suggested that obesity is an important occur-
rence risk factor for EM, and BMI is significantly associated 
with symptoms in EM patients (17). Zhang et al also demon-
strated that DM is associated with EM (5), and several studies 
have reported the association of metabolic markers of obesity, 
including elevated blood glucose, TG and total cholesterol 
levels, with EM (18).
CD and cancer share common risk factors, particularly 
those associated with an unhealthy lifestyle, such as smoking, 
an unhealthy diet, physical inactivity, obesity and alcohol 
Figure 3. Kaplan‑Meier curves for overall survival (OS) in relation to CD according to age (four groups: <50, 50‑59, 60‑69 and ≥70 years) in cervical cancer 
(CC), endometrial cancer (EM) and ovarian cancer (OV) patients.
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intake. CD is known to contribute to >20% of occurrence 
risk factors for various cancers (9); however, to the best of our 
knowledge, this is the first study to describe an association 
between CD and GC, including CC.
In the present study, CD, including HT, DM, DL, HD and 
CVD, were examined in patients with CC, EM and OV. For all 
diseases, we observed a high frequency of EM, CC and OV, in 
decreasing order. For example, HT was observed in 18.2, 28.4 
and 15.8% of CC, EM and OV patients, respectively; DL was 
observed in 5.0, 15.0 and 7.9% of CC, EM and OV patients, 
respectively; DM occurred in 6.0, 13.2 and 5.1% of CC, EM 
and OV patients, respectively; HD was diagnosed in 3.4, 5.1 
and 2.1% of CC, EM and OV patients, respectively; and CVD 
was recorded in 3.5, 2.8 and 2.1% of CC, EM and OV patients, 
respectively. Among the CD patients, 27.6, 43.2 and 24.7% 
had CC, EM and OV, respectively. The incidence of CD was 
found to increase with age in GC patients, with CC patients 
aged >70 years and EM patients aged >60 years accounting 
for >50% of patients with CD. Moreover, the numbers of 
any disease increased with increasing age, regardless of the 
number of CD.
CD were examined for their association with lifestyle 
factors, such as obesity, smoking and alcohol intake, at any age 
in all GC patients. In the present study, CD were more preva-
lent among EM patients compared with CC and OV patients. 
Among the CD patients, 27.6, 43.2 and 24.7% had CC, EM and 
OV, respectively. Of note, occurrence risk factors for EM have 
been established, including HT, DM and DL.
However, there was no association of smoking and alcohol 
intake with CD. We also determined whether CD were associ-
ated with outcome in GC patients, and found that the presence 
of CD was not a prognostic predictor for CC, EM or OV 
patients.
There were certain limitations to the present study. The 
number of patients was relatively small, and the examinations 
were performed at a single institution. Further prospective 
studies involving more patients and multiple institutions 
should provide more definitive data to verify the significance 
of our findings.
In conclusion, the presence of CD appears to contribute to 
>24% of the occurrence risk factors for GC patients in Japan.
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